Point-Of-Care Testing Stirs Anew
This article was originally published in Start Up
Point-of-care diagnostics are back in favor with investors who believe market forces and technological advances are finally converging in ways that invite success and this time, they may be right. Profiles of GeneWEAVE, HiberGene, Spectromics, and Xagenic.
You may also be interested in...
Dublin-based start-up HiberGene Diagnostics Ltd. aims to create rapid, accurate, and simple diagnostic tests for infectious diseases based on LAMP (loop-mediated isothermal amplification) technology, which uses nucleic acid amplification to identify target genes.
Spectromics Ltd. was formed to license and commercialize technology that can detect bacterial susceptibility to drugs in only 10 minutes by detecting the underlying metabolism of pathogens. The start-up aims to incorporate it into a POC test that doctors can use to expose a patient's urine sample to eight different antibiotics, to see which can kill the bugs and which meet resistance.
Anti-infective start-ups getting funded these days say they can boost the odds of clinical success, and reduce the cost of achieving it. Profiles of EnBiotix, Nosopharm, and Spero Therapeutics.